Drugs / PSMA ADC
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01414296 | Jan 2009 → Sep 2013 | prostate cancer | Progenics Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01414283 | Oct 2008 → Apr 2013 | prostate cancer | Progenics Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02020135 | Oct 2013 → Feb 2015 | prostate cancer | Progenics Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01856933 | May 2013 → Nov 2014 | gliosarcoma | Heinrich Elinzano, MD | Completed | No outcome recorded |
| Phase 2 | NCT01695044 | Sep 2012 → Oct 2014 | prostate cancer | Progenics Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSMA ADC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01414283 ↗ |
| Action | Deplete | “Following binding and internalization of PSMA ADC, the cytotoxic component of PSMA ADC will be released and destroy the neovasculature that supports tumor growth.” NCT01856933 ↗ |
| Modality | Other / unclassified | “Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC)” NCT01695044 ↗ |
| Route | Intravenous | “PSMA ADC administered IV” NCT01414283 ↗ |